Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00996 ...
Drug Name Gabapentin
Molecular Weight 171.2368
Molecular Formula C9H17NO2
CAS Number 60142-96-3
SMILES NCC1(CC(O)=O)CCCCC1
External Links
DRUGBANK DB00996
T3DB T3D2952
PubChem Compound 3446
PDR 1404
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 1.25 - 1.25 - Bockbrader, H. et. al. 2010; DPD Label
Water Solubility 100000.0 mg/L >100 mg/ml Bockbrader, H. et. al. 2010
pKa 3.7 - 3.7 - Bockbrader, H. et. al. 2010

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 60.0 % 60 % PO, oral; DRUGBANK
Bioavailability 27.0 % 27 % PO, oral; DRUGBANK
Bioavailability 60.0 % 60.0 % increasing doses ↑ ; The Pharmacological Basis of Therapeutics
C Max 4000.0 ng/ml 4.0 mcg/ml PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 2.5 h 2-3 h DRUGBANK
T Max 2.5 h 2-3 h PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Metabolic 1.0 % 1 % DRUGBANK
Metabolic 99.0 % ~99 % Urinary excretion; Unchanged drug; DRUGBANK
Clearance 0.0960 L/h/kg 1.6±0.3 ml/min/kg Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.10 L/h/kg 1.7 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 58.0 L 58±6 L Apparent volume of distribution; intravenous injection, IV; DRUGBANK
Volume of Distribution 0.80 L/kg 0.80±0.09 L/kg The Pharmacological Basis of Therapeutics
Volume of Distribution 0.71 L/kg 0.71 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 6.0 h 5-7 h elimination half-life; normal renal function; patients; RD, renal impairment, Renal disease，including uremia ↑ ; DRUGBANK
Half-life 52.0 h 52 h Renal clearance; DRUGBANK
Half-life 6.5 h 6.5±1.0 h RD, renal impairment, Renal disease，including uremia ↑ ; The Pharmacological Basis of Therapeutics
Half-life 5.3 h 5.3 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 8000.0 mg/kg >8000 mg/kg DRUGBANK
Toxicity LD50 8000.0 mg/kg >8000 mg/kg PO, oral; Rattus, Rat; T3DB
Toxicity LD50 8053.0 mg/kg 8053.0 mg/kg PO, oral; mouse; T3DB
Toxicity TDLo 2.9 mg/kg 2.86 mg/kg PO, oral; human, homo sapiens; DRUGBANK
Eliminate Route 66.0 % 64-68 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 3.0 % <3 % plasma proteins; PO, oral; DRUGBANK
Protein Binding 3.0 % <3 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 50.0 mg/kg/day 50 mg/kg/day PO, oral Gralise gabapentin PDR
Max dose for adolescents 3600.0 mg/day 3600 mg/day PO, oral Gralise gabapentin PDR
Max dose for adults 3600.0 mg/day 3600 mg/day PO, oral Gralise gabapentin PDR
Max dose for adults 1800.0 mg/day 1800 mg/day PO, oral Gralise gabapentin PDR
Max dose for adults 1200.0 mg/day 1200 mg/day PO, oral Gralise gabapentin PDR
Max dose for geriatric 3600.0 mg/day 3600 mg/day PO, oral Gralise gabapentin PDR
Max dose for geriatric 1800.0 mg/day 1800 mg/day PO, oral Gralise gabapentin PDR
Max dose for geriatric 1200.0 mg/day 1200 mg/day PO, oral Gralise gabapentin PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1